Cargando…

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease

Background: Patients with Crohn’s disease (CD) experience severely reduced quality of life, particularly those who do not respond to conventional therapies. Antitumor necrosis factor (TNF)α is commonly used as first-line therapy; however, many patients remain unresponsive to this treatment, and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Kai, Zhang, Chao, Deng, Minzi, Luo, Weiwei, Ma, Kejia, Xu, Jiahao, Wu, Xing, Yang, Yuanyuan, Wang, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065476/ https://www.ncbi.nlm.nih.gov/pubmed/35517818 http://dx.doi.org/10.3389/fphar.2022.870796

Ejemplares similares

Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease
por: Shen, Zhaohua, et al.
Publicado: (2022)

Assessment of the safety and probiotic properties of Roseburia intestinalis: A potential “Next Generation Probiotic”
por: Zhang, Chao, et al.
Publicado: (2022)

Bacteroides vulgatus alleviates dextran sodium sulfate-induced colitis and depression-like behaviour by facilitating gut-brain axis balance
por: Wu, Xing, et al.
Publicado: (2023)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

LncRNA NEAT1 mediates intestinal inflammation by regulating TNFRSF1B
por: Pan, Shiyu, et al.
Publicado: (2021)

Computational analysis to investigate the anti-rheumatic potential of plant-based small molecule inhibitor targeting tumor necrosis factor α
por: Rehman, Sanaya, et al.
Publicado: (2023)

Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis
por: Chen, Minting, et al.
Publicado: (2021)

Correlation Between Sleep, Life, Mood, and Diet and Severity of Inflammatory Bowel Disease in China: A Retrospective Study
por: Xu, Jiahao, et al.
Publicado: (2021)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy
por: Fukushima, Shinya, et al.
Publicado: (2022)

The Anti-inflammatory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α-Stimulated Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs
por: Li, Meng, et al.
Publicado: (2018)

Azelaic Acid Regulates the Renin–Angiotensin System and Improves Colitis Based on Network Pharmacology and Experimentation
por: Liao, Yangjie, et al.
Publicado: (2023)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
por: Bai, Liang Liang, et al.
Publicado: (2021)

Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Otake, Haruka, et al.
Publicado: (2022)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease
por: Bafutto, Mauro, et al.
Publicado: (2020)

Time and Concentration Dependent Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor α-Induced Endothelial Activation
por: Li, Meng, et al.
Publicado: (2018)

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018)

Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts
por: Hui, Weili, et al.
Publicado: (2017)

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Moroi, Rintaro, et al.
Publicado: (2019)

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study
por: Kwak, Min Seob, et al.
Publicado: (2020)

SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy?
por: Bardasi, Giulia, et al.
Publicado: (2020)

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
por: Ferraro, Sara, et al.
Publicado: (2019)

Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
por: Hu, Yunwei, et al.
Publicado: (2020)

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis
por: Wang, Ziran, et al.
Publicado: (2022)

Piper sarmentosum Promotes Endothelial Nitric Oxide Production by Reducing Asymmetric Dimethylarginine in Tumor Necrosis Factor-α-Induced Human Umbilical Vein Endothelial Cells
por: Sundar, Uma Mahgesswary, et al.
Publicado: (2019)

The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn’s Disease
por: Alourfi, Mansour, et al.
Publicado: (2020)

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
por: Buisson, Anthony, et al.
Publicado: (2022)

Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease
por: Zaidi, Deenaz, et al.
Publicado: (2018)

Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn’s disease after anti-tumor necrosis factor-α therapy
por: Nishida, Nao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_af5sl8soeovjq31e22b01j8iii